Impact of a New Cost-Effectiveness Threshold Implementation on Cancer Formulary Decisions in Jordan Imad TreishAbeer Al RabayahHaitham Tuffaha Practical Application Open access 13 November 2021 Pages: 137 - 145
Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review Ana-Catarina Pinho-GomesJohn Cairns Review Article Open access 20 August 2021 Pages: 147 - 167
Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis Amir AnsaripourKari RoehrichMehdi Javanbakht Original Research Article Open access 01 September 2021 Pages: 169 - 178
Cost Effectiveness of Internet-Delivered Acceptance and Commitment Therapy for Patients with Severe Health Anxiety: A Randomised Controlled Trial Bettina Wulff RisørDitte Hoffmann FrydendalLisbeth Frostholm Original Research Article Open access 08 January 2022 Pages: 179 - 192
Examining Ways to Improve Weight Control Programs’ Population Reach and Representativeness: A Discrete Choice Experiment of Financial Incentives Wen YouYuan YuanPaul A. Estabrooks Original Research Article Open access 10 November 2021 Pages: 193 - 210
Cost of Illness in Patients with Duchenne Muscular Dystrophy in Portugal: The COIDUCH Study Pedro LabisaValeska AndreozziIgor Beitia Ortiz de Zarate Original Research Article Open access 03 October 2021 Pages: 211 - 218
Delineating the Type 2 Diabetes Population in the Netherlands Using an All-Payer Claims Database: Specialist Care, Medication Utilization and Expenditures 2016–2018 Rose J. GeurtenJeroen N. StruijsDirk Ruwaard Original Research Article Open access 04 December 2021 Pages: 219 - 229
Time Trade-Off Utilities for Hereditary Angioedema Health and Caregiver States Siu Hing LoAndrew LloydFloortje E. van Nooten Original Research Article Open access 17 September 2021 Pages: 231 - 239
Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective Will DunlopMarjolijn van KeepAlastair Greystoke Original Research Article Open access 16 September 2021 Pages: 241 - 252
Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada Patrick BerriganGeoffrey G. HicksJennifer D. Zwicker Original Research Article Open access 10 October 2021 Pages: 253 - 263
The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation Ahmed H. SeddikNima MelzerDennis A. Ostwald Original Research Article Open access 19 October 2021 Pages: 265 - 275
Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia Ahmed AlghamdiBander BalkhiRima Aziziyeh Original Research Article Open access 28 September 2021 Pages: 277 - 291
Real-World Treatment Patterns, Outcomes, Resource Utilization and Costs in Treatment-Resistant Major Depressive Disorder: PATTERN, a Retrospective Cohort Study in Belgium B. GillainG. DegraeveI. Vandersmissen Original Research Article Open access 15 November 2021 Pages: 293 - 302
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide Dikshyanta RanaClaudia GeueOlivia Wu Original Research Article Open access 10 November 2021 Pages: 303 - 313